Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Planning and Dissemination Grant - Institute Community Support

University of British Columbia

$25,000.00

Advancing Patent Ductus Arteriosus (PDA) Management in Preterm Infants: A Collaborative Planning and Dissemination Initiative in Canada

EF 2025-26

Résumé
The management of patent ductus arteriosus (PDA), a common heart condition in premature infants, has been a complex challenge in newborn care. In 2022, the Canadian Paediatric Society (CPS) recommended conservative management of PDA, meaning no intervention during the first 1-2 weeks after birth. However, new evidence has emerged which raises important questions about the best ways to identify and treat PDA in the smallest babies. An updated Cochrane Systematic Review, including 5 new clinical trials, found that there was possibly a higher risk of death with early use of drugs such as ibuprofen to close the PDA in extremely preterm babies. However, the results of two recent Canadian Institutes of Health Research (CIHR-) funded studies do not completely align with these findings. The SMART- PDA trial found that selective early treatment might improve survival without major health conditions in infants born before 26 weeks, highlighting the potential benefits of early targeted treatment. The CANRxPDA study showed that while PDA treatment may improve survival, the risks of chronic lung disease and necrotizing enterocolitis are increased. These findings further complicate clinical decision-making for PDA management. Therefore, we need to bring together families, healthcare providers and researchers to decide on the next steps for clinical care and research priorities. Our initiative aims to ensure treatment decisions are based on the latest evidence and align with family values and preferences. Key activities include: (1) integrating family perspectives by prioritizing clinical outcomes, (2) convening a panel of stakeholders to review the evidence using the GRADE Evidence to Decision framework, and (3) providing recommendations to the national organizations for updating guidelines and guiding future research. This project aligns with CIHR's mandate by promoting collaboration and advancing research to improve care for Canadian children born preterm and their families.
Programme
Planning and Dissemination Grant - Institute Community Support
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
531392
Name
Mitra Souvik
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Human Development, Child and Youth Health
Theme2
Clinical
Prcname2
Planning and Dissemination Grants
Projecttitle
Advancing Patent Ductus Arteriosus (PDA) Management in Preterm Infants: A Collaborative Planning and Dissemination Initiative in Canada
Programtype2
Miscellaneous Programs
Orgnameinp2
University of British Columbia
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
Planning and Dissemination Grant - Institute Community Support
Keyworddelim
Patent Ductus Arteriosus; Preterm Infant
Abstract
The management of patent ductus arteriosus (PDA), a common heart condition in premature infants, has been a complex challenge in newborn care. In 2022, the Canadian Paediatric Society (CPS) recommended conservative management of PDA, meaning no intervention during the first 1-2 weeks after birth. However, new evidence has emerged which raises important questions about the best ways to identify and treat PDA in the smallest babies. An updated Cochrane Systematic Review, including 5 new clinical trials, found that there was possibly a higher risk of death with early use of drugs such as ibuprofen to close the PDA in extremely preterm babies. However, the results of two recent Canadian Institutes of Health Research (CIHR-) funded studies do not completely align with these findings. The SMART- PDA trial found that selective early treatment might improve survival without major health conditions in infants born before 26 weeks, highlighting the potential benefits of early targeted treatment. The CANRxPDA study showed that while PDA treatment may improve survival, the risks of chronic lung disease and necrotizing enterocolitis are increased. These findings further complicate clinical decision-making for PDA management. Therefore, we need to bring together families, healthcare providers and researchers to decide on the next steps for clinical care and research priorities. Our initiative aims to ensure treatment decisions are based on the latest evidence and align with family values and preferences. Key activities include: (1) integrating family perspectives by prioritizing clinical outcomes, (2) convening a panel of stakeholders to review the evidence using the GRADE Evidence to Decision framework, and (3) providing recommendations to the national organizations for updating guidelines and guiding future research. This project aligns with CIHR's mandate by promoting collaboration and advancing research to improve care for Canadian children born preterm and their families.
Competitiondate
202506
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mitra, Souvik; Richter, Lindsay L
Approvedterm
1 an 0 mois
Cihrcontribution2
IHDCYH~ $25,000~ $0~